Publications
86
Citations
1,821
Est. group size
~17
Recurring co-author estimate
Active years
20
Publishing since 2007
Typically publishes in teams of ~14 · 6% small-team papers (≤3 authors) · across 6 venues
- The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Journal of Clinical Oncology · 2026
- Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology · 2026
- Association of the 70-gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.
Journal of Clinical Oncology · 2026
- The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Scholar Commons (University of South Carolina) · 2026
- Abstract RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer
Clinical Cancer Research · 2025
- Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX.
Journal of Clinical Oncology · 2025
- Abstract P4-09-22: Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC)
Clinical Cancer Research · 2025
- Data from Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
2025
- Supplementary Figure 1 from Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
2025
- Supplementary Tables 1 from Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
2025
- Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Journal of Clinical Oncology · 2024
- Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
Clinical Cancer Research · 2024
- Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
Journal of Clinical Oncology · 2024
- Abstract PO3-02-04: Comparison of OncotypeDX Recurrence Scores (RS) and MammaPrint (MP) scores, and chemotherapy indications in early-stage Estrogen Receptor positive/HER2 negative (ER-/HER2-) breast cancer
Cancer Research · 2024
- MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
Journal of Clinical Oncology · 2023
- Journal of Clinical Oncology×16
- Clinical Cancer Research×7
- Cancer Research×7
- International Journal of Radiation Oncology*Biology*Physics×3
- JAMA Oncology×2
- Sagar Sardesai
Medicine · The Ohio State University
- Anne F. Schott
Medicine · University of Michigan
- Preeti Sudheendra
Medicine · The Ohio State University
- Jiayu Wang
Medicine · University of Michigan
- Mehta Rs
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile